...
首页> 外文期刊>Journal of Vascular and Interventional Neurology >Local Intrasinus Thrombolysis for Cerebral Venous Sinus Thrombosis
【24h】

Local Intrasinus Thrombolysis for Cerebral Venous Sinus Thrombosis

机译:局部鼻窦内溶栓治疗脑静脉窦血栓形成

获取原文
           

摘要

Background Cerebral venous strokes due to cerebral venous sinus thrombosis (CVST) have varied presentation and clinical outcome. Despite aggressive medical treatment with optimal anticoagulation, some patients develop progressive neurologic deterioration causing significant morbidity and mortality. The aim of the present series is to analyze the safety and efficacy of in situ thrombolysis in patients with cerebral venous sinus thrombosis in severe clinical grade and refractory to conventional medical management. Materials and methods Twenty-nine patients with cerebral venous thrombosis who received in situ thrombolysis during a 3-year period (April 2013 to April 2016) were included in the study. Tissue plasminogen activator (tpa) was used in all the patients. The lytic agent was infused into the sinus via the micro catheter. Data regarding demographic, clinical, and radiologic features were analyzed in all the patients. Results Recanalization of the affected sinuses was achieved in all the cases. Twenty-four patients had good outcome (mRs 0 or1) and three patients had mild deficits (mRs 2). One patient had moderate disability (mRs 3). One patient succumbed due to increased hematoma causing midline shift and transtentorial herniation. At 3 months follow–up, 26 patients were asymptomatic and two patients had minor symptoms. Conclusion Local intrasinus thrombolysis (LIST) is safe and effective method in patients with poor clinical grade and the present study highlights the benefit of thrombolysis, particularly in patients unresponsive to anticoagulation. The improved efficacy of this therapy depends on early recognition of worsening symptoms and timely intervention.
机译:背景由于脑静脉窦血栓形成(CVST)引起的脑静脉中风有多种表现和临床结果。尽管积极的药物治疗和最佳的抗凝治疗,一些患者仍发展为进行性神经系统恶化,导致明显的发病率和死亡率。本系列文章的目的是分析在严重临床分级且常规治疗难以治疗的脑静脉窦血栓形成患者中原位溶栓的安全性和有效性。材料和方法研究对象为29名在3年期间(2013年4月至2016年4月)接受原位溶栓治疗的脑静脉血栓形成患者。所有患者均使用组织纤溶酶原激活剂(tpa)。通过微导管将溶解剂注入鼻窦。在所有患者中分析了有关人口统计学,临床和放射学特征的数据。结果所有病例均实现了鼻窦再通。 24例患者预后良好(mRs 0或1),三例患者出现轻度缺陷(mRs 2)。一名患者患有中度残疾(mRs 3)。一名患者因血肿增加而致死,引起中线移位和跨膜疝。随访3个月,无症状26例,轻度症状2例。结论局限性鼻窦内溶栓(LIST)治疗临床分级差的患者是安全有效的方法,本研究强调了溶栓的益处,特别是对抗凝治疗无反应的患者。这种疗法的疗效提高取决于症状的早期发现和及时干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号